Efficacy and safety maintained in patients who switched from Humira® to biosimilar Cyltezo®
Boehringer Ingelheim today announced one-year data from VOLTAIRE®-RA, a pivotal Phase III clinical trial comparing Cyltezo® (adalimumab-adbm) and reference product Humira®*. The 48-week data showed that Cyltezo® is equivalent, with no clinically meaningful differences in efficacy, safety and immunogenicity to Humira® in people with moderately-to-severely active rheumatoid arthritis (RA), including in patients who switched from Humira® to Cyltezo® at week 24.1
“These data are an important addition to the robust body of evidence demonstrating Cyltezo® is biosimilar to Humira®,” said Karsten Kissel, MD, Head of Global Medical Affairs Biosimilars at Boehringer Ingelheim. “Biosimilars have potential cost benefits to the healthcare system and support affordable access to important biologic medicines for patients living with chronic inflammatory diseases like RA.”
“In addition to the 48-week efficacy results, the adalimumab biosimilar Cyltezo® showed equivalent safety and immunogenicity to Humira®,” said Stanley B. Cohen, MD, Metroplex Clinical Research Center, Presbyterian Hospital, Dallas, Texas. “Consistent results were also demonstrated when patients were switched to Cyltezo® from the reference product.”
These data will be presented at the American College of Rheumatology / Association of Rheumatology Health Professionals Annual Meeting in San Diego, California.
In the EU, Cyltezo® recently received positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for multiple chronic inflammatory diseases including, in adults:
- Moderate to severely active rheumatoid arthritis
- Psoriatic arthritis
- Moderate to severely active Crohn's disease
- Severe active ankylosing spondylitis
- Moderate to severely active ulcerative colitis
- Severe axial spondyloarthritis without radiographic evidence of AS
- Moderate to severe chronic plaque psoriasis
- Moderate to severe hidradenitis suppurativa
- Non-infectious intermediate, posterior and panuveitis.
The CHMP also recommended approval of Cyltezo® for the treatment of paediatric inflammatory diseases, including moderate to severe Crohn's disease (age six and older), severe chronic plaque psoriasis (age four and older), enthesitis-related arthritis (age six and older) and polyarticular juvenile idiopathic arthritis (age two and older).
Cyltezo® is not commercially available in Europe or the U.S. at this time. In any event Boehringer Ingelheim does not intend to launch Cyltezo® in the EU before expiration of the respective SPC for adalimumab in October 2018. Boehringer Ingelheim is currently engaged in patent litigation with AbbVie in the U.S.
This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.
For references and notes to editors, please visit : http://www.boehringer-ingelheim.com/press-release/one-year-data-showing-cyltezo-equivalent-humira
Media + PR
Dr. Julia Knebel
Phone: +49 6132 – 77 95614
Fax: +49 6132 – 77 6601
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Rockwell Automation Opens Registration for 2018 Automation Fair18.9.2018 14:54 | Pressemelding
Registration is now open for the 2018 Automation Fair, hosted by Rockwell Automation and members of its global PartnerNetwork program. The 27th annual Automation Fair will be held Nov. 12-15 at the Pennsylvania Convention Center. The event brings together approximately 10,000 manufacturers and producers from across the globe to learn about the newest innovations in automation and take part in training, industry forums and networking events. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180918005725/en/ Automation Fair will feature more than 150 exhibits showcasing the latest product innovations for industrial manufacturing and production. Hosted by Rockwell Automation and members of its PartnerNetwork, the event offers more than 400 hours of educational opportunities through forums, hands-on labs and technical sessions. (Photo: Business Wire) “The next industrial transformation is here – and meeting its demands requires a m
Seoul Semiconductor Supplies Optimal LEDs ‘SunLike’ to Large Scale Applications of Lumitronix in Germany18.9.2018 13:33 | Pressemelding
Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), a market leader in LED (light emitting diode) design and manufacturing, supplied the innovative LEDs “SunLike” to Lumitronix, the LED specialist located in Baden-Württemberg, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180918005626/en/ The Modules with SunLike LEDs. (Photo: Business Wire) In cooperation with Seoul Semiconductor, Lumitronix has also developed three optimal SunLike modules to provide customers with a standardized solution and expand its adoption in the lighting market. Two of the LED modules comply with the standard of Zhaga, a global association of lighting companies, for Book 7 L56W2 and Book 7 L28W2 and enable easy replacement in various industrial applications. The modules named LinearZ are available in one feet and two feet length. The model LinearZ 280-26 measures 280 mm and is equipped with 26 SunLike LEDs and has a light output of up to 700 lm.
Andersen Global Continues South American Expansion With BKM Berkemeyer18.9.2018 13:30 | Pressemelding
Andersen Global announces further growth in South America with the signing of a Collaboration Agreement with BKM Berkemeyer, one of the oldest and largest law firms in Paraguay. With two locations in the capital city of Asunción, the firm has a headcount of nearly 150 professionals, including ten Partners and over 60 lawyers. Established in 1951, BKM Berkemeyer is led by Managing Partner Hugo Berkemeyer and provides legal solutions to both domestic and international clients. The firm delivers advice in all areas of law, including business and corporate, taxation, litigation, environment, employment and intellectual property, with a notable expertise in international transactions and business matters. BKM Berkemeyer also specializes in M&A’s, joint ventures, foreign investment, infrastructure, project finance and financial transactions, advising also on issues regarding telecommunications, water and energy projects. Hugo commented, “Our focus at BKM Berkemeyer has been to provide flexib
175 Million Europeans Have Sleep Apnoea, Highlighting Scale of Global Health Crisis18.9.2018 13:05 | Pressemelding
Roughly 175 million Europeans have obstructive sleep apnoea, according to a late-breaking abstract presented by ResMed today at the European Respiratory Society’s annual ERS Congress in Paris. Leading researchers estimate 90 million Europeans have moderate to severe sleep apnoea, meaning they experience at least 15 breathing events an hour during sleep. These statistics are based on the latest scoring rules for determining one’s apnoea–hypopnoea index (AASM 2012) and are connected with a 16-country study announced in May 2018 that revealed an estimated 936 million people worldwide have sleep apnoea, a chronic sleep-disordered breathing condition associated with increased risk of mortality and reduced quality of life. The new global prevalence is nearly tenfold higher than the previous one – 100 million – estimated by the World Health Organization in 2007. European countries with the highest prevalence are: Russia, 40 million Germany, 26 million France, 24 million Ukraine, 13 million Sp
Loomis Sayles Announces Senior Loan Portfolio Manager Retirement18.9.2018 13:00 | Pressemelding
Loomis, Sayles & Company, an affiliate of Natixis Investment Managers, announced today that Kevin Perry, portfolio manager on the senior loan team, will retire in March 2019 after 17 years with the company and 37 years in the industry. All senior loan portfolios will continue to be co-managed by portfolio managers John Bell and Michael Klawitter, who have been members of the team for 17 and 16 years, respectively. The team oversees approximately $10.7 billion1 in institutional and retail assets for global clients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180918005187/en/ “Kevin has embodied Loomis Sayles’ values of collaboration, humility and prudent risk-taking every day since he and John joined us in 2001,” said Kevin Charleston, chief executive officer. “Kevin and John are considered pioneers in the bank loan market and their efforts have led to clients entrusting us with the management of more than $10 billion in b
SIA Has Provided the New Real-Time Gross Settlement System in Denmark18.9.2018 13:00 | Pressemelding
SIA, European hi-tech company, leader in payment infrastructures and services, has further strengthened its positioning in the Nordic countries, by providing Danmarks Nationalbank with the new real-time gross settlement system (RTGS) that connects banks, mortgage banks and settlement systems. This RTGS platform is already in operation by the central banks of Norway and Sweden and it will soon go live in Iceland too. The up-to-date technology infrastructure developed by SIA has replaced the previous in-house system that has been in use by the Central Bank of Denmark since 2001. The new RTGS system, that secures safe and real-time transfer of Danish kroner, ensures continued efficiency, operational reliability, functional sophistication and simpler maintenance of the system. In this initiative, SIA has used its wholly-owned subsidiary Perago, based in Pretoria (South Africa) and specialized in central bank solutions. Later this year, Denmark will be the first non-euro country to particip